- 64 Aufrufe
Neue Studien
- 78 Aufrufe
Patients with moderate-to-severe psoriasis often experience significant physical symptoms and notable psychosocial distress. Pruritus is the most bothersome symptom and a key contributor to sleep disturbances and reduced quality of life (QoL). Though biologics such as risankizumab have advanced clinical management, real-world evidence of patient-reported outcomes (PROMs) and objective pruritus assessment remains limited. This study assessed risankizumab's effectiveness in improving QoL, symptom burden, and sleep and evaluated the feasibility of nocturnal scratch monitoring using a wearable sensor.Methods
PRIMMA was a multicenter, prospective, non-interventional study conducted in Israel among adults with moderate-to-severe psoriasis initiating label-approved risankizumab therapy. Outcomes were assessed at baseline and week 52, and included Dermatology Life Quality Index (DLQI), static Psoriasis Global Assessment (sPGA), Pruritus Numeric Rating Scale (PNRS), Psoriasis Symptoms Scale (PSS), Medical Outcomes Study Sleep Scale (MOS-SS), Work Productivity and Activity Impairment (WPAI), and adverse events. Objective nocturnal scratch activity was measured using ADAM digital patch sensors in a subgroup of patients.Results
In 136 participants, the median age was 51 years, 57% were male, 43% were female, and 35% were bio-naïve. At week 52, 58% achieved DLQI 0/1 (versus 5.1% at baseline; p < 0.001) and 81% had PNRS 0-3 (versus 21% at baseline; p < 0.001). sPGA 0/1 was reached by 77% at week 52, and components of PSS and WPAI improved significantly. In patients who achieved any favorable outcome (DLQI 0/1, PNRS 0-3, sPGA 0/1) at week 24, ≥ 68% maintained it at week 52, demonstrating treatment durability. In the digital subcohort (n = 14), sensor data confirmed significant reduction in nocturnal scratch duration at week 4 and week 16 compared to baseline (both p ≤ 0.032). Adverse events were mostly mild to moderate.Conclusions
In real-world practice, risankizumab showed substantial improvements in QoL, pruritus, sleep, and work/activity impairment in moderate-to-severe psoriasis. Digital scratch monitoring showed reduction in nocturnal scratch duration. Integrating objective digital measures with PROMs may enable more data-driven, individualized management in psoriasis care.Clinical trial registration
ClinicalTrials.gov Identifier NCT04780516.Weiterlesen
- 72 Aufrufe
- 70 Aufrufe
- 72 Aufrufe
- 81 Aufrufe
Up to one-third of people living with psoriasis develop psoriatic arthritis (PsA), and the majority have active psoriasis prior to the development of arthritis. Clinical risk factors, such as nail involvement, in conjunction with novel blood biomarkers, could improve PsA risk monitoring and early diagnosis.Objectives
The aim of the HIPPOCRATES Prospective Observational Study (HPOS-www.hpos.study) is to follow a cohort living with psoriasis and identify risk factors for the development of PsA.Design
HPOS is a patient-driven online prospective European observational cohort.Methods
Adult participants with psoriasis but with no prior diagnosis of PsA are eligible. Participants are invited to provide consent and join the study online. They complete a semi-structured questionnaire to collect data on demographics, psoriasis, comorbidities, risk factors for PsA, and the Psoriasis Epidemiology Screening Tool screening questionnaire. Follow-up is conducted through a questionnaire every 6 months. The primary outcome is the new onset of PsA confirmed by a diagnosis from their doctor. The study will also collect peripheral blood samples from a subset of participants for biomarker identification.Ethics
This study follows the principles of the Declaration of Helsinki. To date, ethical approval has been granted by independent ethical committees in 10 countries.Discussion
Studying a cohort of individuals with psoriasis will allow us to identify risk factors for arthritis development and to develop a risk calculator. This can support focused efforts on screening, patient education, and even studies looking to delay or prevent the onset of arthritis. This study, run via remote online data collection, provides an efficient way to recruit a large cohort (25,000) across multiple countries. However, challenges have had to be addressed with some key changes in study design, ethical review, and recruitment strategies required for each individual country.Trial registration
HPOS, Clinicaltrials.gov ID: NCT05858528, IRAS number 325080; https://clinicaltrials.gov/study/NCT05858528?locStr=United%20Kingdom&country=United%20Kingdom&cond=Psoriasis&term=HPOS&aggFilters=status%3Anot%20rec&rank=1.Weiterlesen
- 55 Aufrufe
- 80 Aufrufe
- 68 Aufrufe
- 69 Aufrufe
Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases that affect not only the skin and joints but also the cardiovascular system.Aim
To investigate the relationship between epicardial adipose tissue (EAT) thickness and anthropometric measurements, laboratory parameters, and clinical variables in patients with psoriasis and PsA.Methods
This cross-sectional study included 65 patients with psoriasis vulgaris (with or without PsA) and 54 healthy controls. Demographic, clinical, and laboratory data of the participants were recorded. EAT, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), interventricular septum thickness (IVS), and ejection fraction (EF) were measured by echocardiography. Associations between EAT thickness and patient parameters were evaluated using Spearman correlation and multivariate linear regression analyses.Results
The mean ages of the patient and control groups were 43.88 ± 13.1 years and 44.81 ± 12.88 years, respectively. Low-density lipoprotein cholesterol, LVESD, and IVS were significantly higher in the control group compared with psoriasis patients (P = 0.021, P < 0.001, P < 0.001, respectively). C-reactive protein (CRP) levels (P < 0.001), systolic blood pressure (P < 0.001), diastolic blood pressure (P = 0.023), and EAT thickness (P < 0.001) were significantly higher in the patient group. Disease duration (P = 0.028) and PASI (P = 0.012) were significantly greater in psoriasis patients with PsA. EAT positively correlated with body mass index (BMI) (r = 0.307, P = 0.024), CRP (r = 0.344, P < 0.001), and systolic blood pressure (r = 0.185, P = 0.044).Conclusions
EAT thickness was higher in patients with psoriasis than in control participants. EAT positively correlated with BMI, CRP, and systolic blood pressure.Weiterlesen
- 80 Aufrufe
Palmoplantar psoriasis exhibits greater treatment resistance compared to other psoriatic plaques and presents clinical and histopathological overlap with palmoplantar eczema. This study aimed to investigate treatment resistance mechanisms in palmoplantar psoriasis and assess the contribution of IL-17, IL-23, and IL-36α to the differential diagnosis of palmoplantar psoriasis and eczema. Immunohistochemical levels of these cytokines were measured in paired acral and non-acral psoriatic samples.Methods
We retrospectively included 73 patients: 25 with only palmoplantar psoriasis, 25 with palmoplantar eczema, and 23 with both conditions and concurrent plaque psoriasis. Clinical and histopathological diagnoses were confirmed. Immunohistochemical analyses were conducted using preparations stained for IL-17, IL-23, and IL-36α.Results
In psoriasis cases, immunohistochemical examination of biopsies from both body and palmoplantar regions showed lower IL-17 and IL-36α expression in acral regions compared to non-acral regions. In palmoplantar eczema patients, IL-17 and IL-23 expression was higher than in palmoplantar psoriasis patients; however, IL-36α expression was similar in both conditions.Conclusions
The diminished expression of IL-17 and IL-36α in palmoplantar psoriasis compared to other body sites may contribute to variable responses to targeted treatments. These findings suggest the potential for developing distinct biological treatments for these regions.Weiterlesen
- 68 Aufrufe
- 74 Aufrufe
- 72 Aufrufe
Psoriasis is recognized as a systemic inflammatory disease associated with metabolic dysregulation. Understanding these metabolic changes may reveal biomarkers to elucidate disease mechanisms and predict comorbidities. While previous studies have identified psoriasis-associated metabolites, findings are often limited by sample sizes and lack validation.Objectives
To identify circulating metabolites associated with psoriasis, including disease severity and psoriatic arthritis. Further, we investigated whether the metabolic signature was disease-specific compared to other immune-mediated inflammatory diseases (IMIDs).Methods
We performed a cross-sectional analysis of 470,352 White/European individuals from the UK Biobank (n=453,428) and HUNT (n=16,924). Nuclear Magnetic Resonance spectroscopy was used to quantify metabolite levels, covering lipoprotein fractions and subfractions, fatty acids, and small-molecular metabolites. For each metabolite, we performed multivariable linear regression adjusting for age, sex, BMI, smoking status, and use of lipid-lowering medications.Results
The metabolomic profile of psoriasis was largely consistent across the two populations. In the model adjusted for age and sex, 123 metabolic measures were associated with psoriasis. After full adjustment, only Glycoprotein acetyls (GlycA) remained associated with psoriasis (coefficient [95% CI]: 0.09 [0.07-0.11] in UK Biobank and 0.11 [0.06-0.17] in HUNT). In HUNT, severe psoriasis exhibited more pronounced metabolic alterations compared to non-severe psoriasis. Across both populations, phenylalanine levels were highly elevated in psoriatic arthritis compared to cutaneous psoriasis (0.44 [0.29-0.60] in UK Biobank and 0.47 [0.28-0.67] in HUNT). In comparisons across IMIDs, atopic dermatitis and cutaneous-limited psoriasis exhibited milder metabolic alterations, and psoriasis in HUNT showed a distinct lipoprotein profile.Conclusions
This large-scale study confirms metabolic alterations in individuals with psoriasis and highlights phenylalanine as a potential biomarker for joint involvement in psoriasis. The distinct metabolomic profile of psoriasis relative to other IMIDs suggests a potentially unique systemic profile. These findings offer a foundation for advancing biomarker research and mechanistic studies for psoriasis.Weiterlesen
- 75 Aufrufe
- 66 Aufrufe
We aimed to identify and characterize distinct subgroups of patients with psoriatic arthritis (PsA) based on their responses to the Assessment of SpondyloArthritis international Society Health Index (ASAS HI), using latent class analysis (LCA).Methods
We performed an exploratory LCA on 17 dichotomous ASAS HI items in a cohort of patients with PsA (n = 90). Model adequacy was evaluated by log-likelihood, Akaike information criterion (AIC), Bayesian information criterion (BIC), entropy, and average posterior probabilities (AvePP). Clinical measures (Psoriatic Arthritis Impact of Disease [PsAID], Disease Activity Index for Psoriatic Arthritis [DAPSA], tender/swollen joint counts, treatment) were compared across classes. Sensitivity analyses with 3 to 4 classes assessed robustness.Results
A 6-class solution was retained, ordered from class 0 (lowest impact) to class 5 (highest impact). Mean ASAS HI ranged from 1.2 in class 0 to 11.6 in class 5, with parallel increases in PsAID and DAPSA. Conditional probabilities revealed distinct profiles: class 0 had minimal impairment, classes 1-2 showed predominantly physical function limitations of mild to moderate severity, class 3 combined physical and emotional function burden, class 4 was characterized by dominant participation and social impact, and class 5 displayed severe multidimensional impairment. All classes had AvePP > 0.86. Sensitivity analyses with K = 3 and K = 4 reproduced the same gradient of impact but provided less granular separation.Conclusion
LCA of the ASAS HI identified 6 clinically meaningful health impact profiles in PsA. These findings support the use of the ASAS HI as a multidimensional tool capable of capturing diverse patient experiences and may help inform individualized management strategies in PsA.Weiterlesen
- 63 Aufrufe
Atopic dermatitis and psoriasis are chronic inflammatory skin diseases often linked to psychological stress. Integrative care models are lacking. This randomized pilot study aimed to develop and test a psychoeducational intervention for dermatology patients.Patients and methods
Patients with a PHQ-2 score ≥ 3 at an outpatient inflammation center were randomized into an intervention or control group. The intervention group received three standardized educational sessions focusing on maladaptive schemas, coping strategies, psychoeducation, and emotion-focused techniques (e.g. chair-dialogues, imaginary rescripting).Results
19 patients received the intervention; 13 were in the control group. Post-intervention, significant improvements were observed in dermatological quality of life (DLQI), subjective well-being (WHO-5), and depressive symptoms (PHQ-9, BDI-II). Psychological benefits were largely independent of disease severity (PASI, EASI). Qualitative feedback highlighted usability, learning specific techniques, and a trusting therapeutic relationship.Conclusions
A brief psychoeducational intervention significantly reduced psychological stress in dermatology outpatients. Further studies are needed to evaluate long-term effects and broader implementation.Weiterlesen
- 88 Aufrufe
- 69 Aufrufe
Psoriasis is one of the chronic inflammatory skin conditions, affecting about 2-3% of the world population. Steroidal treatment are only best choice of treatments, but it is often associated with side effects due to higher lipophilicity.Objectives
In this work, a nanoparticle-loaded transdermal film was developed to maintain nanoparticle integrity in the skin.Methods
Fluticasone propionate loaded chitosan nanoparticles (NPs) were developed, and their particle size, zeta potential, drug loading, entrapment efficiency and scanning electron microscope (SEM) images were determined. The NPs-loaded film was further characterized for appearance, thickness and Fourier Transform Infrared (FTIR) spectra, and an in vitro and in vivo permeation study was conducted.Results
The particle size of FSNPs was found to be 250nm with +32.4 ±1.5 mV zeta potential, great entrapment efficiency and spherical in shape. In vivo dermato-kinetic studies showed long-term, confined drug release from the NP-formulated film in the epidermal layers, compared with the film containing free drug.Conclusion
The study demonstrated that the FSNPs-loaded film showed higher skin permeation, which is effective for managing psoriasis and warrants further evaluation.Weiterlesen
- 82 Aufrufe
- 77 Aufrufe
- 63 Aufrufe
- 77 Aufrufe
- 70 Aufrufe